Facing Our Risk of Cancer Empowered   Report issue

Foundation Phase 3
Founded: Tampa FL United States

Organization Overview

First Clinical Trial
2013
NCT01847274
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

niraparib (zejula) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Hypersensitivity (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1